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rare disease, is a target for enzyme replacement therapies, yet UCD epidemiology 
data are scarce. The objective of this study is to estimate the prevalence of UCD 
in the 0–17 year-old population in five major European markets (EU5) (France, 
Germany, Italy, Spain, UK). Methods: We designed an incidence-survival model 
utilizing birth incidence, annual life-expectancy and country-specific newborn 
data. Birth incidence estimates for UCD were obtained from the Urea Cycle 
Disorders Consortium (UCDC). We conducted a literature review to determine 
the annual life expectancy of UCD. Finally, we reviewed available EU5 newborn 
census data to obtain the number of newborns in each country from 2001 to 2012. 
We extrapolated the trend from 2001-2012 to forecast the number of newborns 
through 2024. These data were entered into the incidence-survival model to calcu-
late the prevalence of UCD from 2015-2024. Results: We estimated a prevalence 
of 1.71 per 100,000 population in the 0–17 year age groups resulting in 1,027 and 
1,033 UCD cases in the EU5 in 2015 and 2024, respectively. The prevalence was 1.89 
per 100,000 in the 0-4 year-old age group, 1.63 per 100,000 in the 10-14 year-old 
age group, and 1.57 per 100,000 in 15-17 year-old age group. ConClusions: To 
our knowledge, this study provides the first prevalence estimate of UCD in the 
EU5 markets. With 1,027 estimated cases in 2015, it is expected that UCD treat-
ments will be expensive given the small size of the patient population. Further, 
these estimates can be used to approximate the total cost burden of UCD and the 
resulting cost-effectiveness of UCD treatments.
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objeCtives: To explore the relationships between characteristics of patients 
with multiple myeloma (MM) and clinical and economic outcomes to identify 
which patient subgroups contribute the greatest clinical and economic bur-
dens. Methods: Literature was systematically searched for relevant articles pub-
lished between 2004 and 2014. A database of patient characteristics, outcomes and 
subgroup-specific information was created and analysed to explore relationships 
between patient characteristics and outcomes. The coefficient of determination 
(R2) was calculated to examine the strength of these relationships to help to formu-
late hypotheses for further research. Results: Objective response rate (ORR) and 
overall survival (OS) were the most commonly reported outcomes, while economic 
outcomes data were limited. Although patient characteristics varied across studies, 
several trends were observed. There was a weak correlation between increasing 
age and higher OS (R2 = 0.0185) and ORR (R2 = 0.0305). OS decreased (R2 = 0.2428) 
as the proportion of patients with International Staging System (ISS) stage III MM 
increased; however, only five studies reported OS by ISS subgroup. ORR decreased (R2 
= 0.2843) as the proportions of patients with no prior stem cell transplantation (SCT) 
increased and a small decrease in OS was observed (R2 = 0.0280), but SCT eligibility 
did not demonstrate consistent outcome trends. A trend towards increased OS was 
seen with previous treatment with bortezomib (R2 = 0.3057) or thalidomide (R2 = 
0.2612). In contrast, previous treatment with these agents was associated with a 
worse ORR (R2 = 0.1926 and R2 = 0.2617, respectively). ConClusions: SCT status 
and prior therapies appear to affect outcomes, and a trend was seen between ISS 
stage III MM and poor prognosis. This exploratory approach has generated hypoth-
eses for further research into how patient characteristics influence resource use 
and cost. A better understanding of how patient factors impact on outcomes may 
facilitate better targeting of treatment.
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objeCtives: The objective of the study was to provide a comprehensive overview 
of existing risk prediction models of mortality, complications, and remission of 
diabetes after bariatric surgery. Methods: A systematic literature review was 
performed in Medline, Medline-In-Process, EMBASE, and the Cochrane Central 
Register of Controlled Trials (CENTRAL) databases in April 2015. All English lan-
guage full-text published derivation and validation studies for risk prediction mod-
els focusing on safety and diabetes outcomes of bariatric surgery were included. 
Two reviewers independently performed screening of the studies. Data extraction 
included population, outcomes, variables, intervention, model discrimination, 
and calibration. Results: Of the 2331 studies retrieved from the search, only 
25 studies met the inclusion criteria. Of these, 20 presented development of risk 
prediction models/scores, and five reported validation of existing models. Six 
models were each developed to predict mortality (in-hospital, at 30 days, 90 days, 
and ten years), complications (during perioperative, at 30 days, and 90 days), and 
remission of type 2 diabetes (post-operative, and at one year); and two models 
developed to predict both mortality and complications (at 30 days). Internal valida-
tion using bootstrap resampling or tenfold validation was reported for six models, 
while five models had external validation using independent patient cohorts: 
ABCD score (remission of type 2 diabetes at one year), DiaRem Score (remission 
of type 2 diabetes at one year), Gupta’s model (remission of type 2 diabetes at one 
year), Maciejewski’s model (complication at 90 days), and OS-MRS (mortality at 
90 days). Models included on average 6.9±3.5 variables (range 2-13). Calibration 
and discrimination statistics were not reported for all models. ConClusions: 
There are a variety of risk prediction models for safety and diabetes outcomes of 
bariatric surgery available. However, only few models have undergone external 
group 15-45 were included for study. According to WHO, anemia in non-pregnant 
women age 15-45 years were classified as mild (110-119g/l), moderate (80-109g/l) 
and severe (less than 80g/l) on the basis of hemoglobin concentration. Results: 
A total of six studies satisfy the inclusion criteria were included for study purpose. 
It includes a total of 4684 anemic women ranging from 26 to 3835 from different 
rural and urban parts of India. The overall prevalence of anemia from the pooled 
estimates was 53.2% (95% CI, 41.1-64.9). Prevalence in rural and urban parts of India 
was found to be 55.2% (95% CI, 12.6-41.5) and 49.5% (95% CI 32.9-66.3), respectively. 
Among all the anemic patients cases, mild 31.6% (95% CI, 30.2-33.0) contributes 
maximum number of patients followed by moderate 19.3% (95% CI, 18.1-20.6), and 
severe 2.2% (95% CI, 1.8-2.7). ConClusions: Anemia is highly prevalent in Indian 
women. Nearly equal prevalence was reported from both rural and urban women 
population. Mild form of anemia was found to be more prevalent.
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objeCtives: Anemia and iron deficiency are common during pregnancy and 
expose mothers to several risks such lower resistance to infections or reduced 
tolerance to significant blood loss and to surgical interventions during labor. 
Regarding the foetus, presumed risks include unfavourable obstetric outcomes, 
notably, premature birth, low birth weight and fetal death. The present study aims 
at exploring the prevalence of iron deficiency and anemia among pregnant women 
in France and at evaluating the management of these conditions. Methods: A 
prospective observational study was conducted in France between March 2013 and 
June 2014. Randomly selected investigators (gynecologists, obstetricians, midwives 
registered in the CEGEDIM® database) were asked to include consecutive pregnant 
women presenting for a consultation. At study inclusion, a two-section question-
naire was completed by both the patient (self-assessment) and the investigator. 
Data collected consisted in age, gestation week, laboratory values (e.g. Hb, fer-
ritin), type and reason for the prescription of medication and lifestyle or dietary 
advice given/received. Results: 1506 patients were enrolled by 95 centres and 
data were analyzed for 1478 women. Investigators estimated that almost 60% of 
women were at moderate or significant risk of iron deficiency. Ferritin levels was 
< 15 µg/L in 30.9% of individuals (18.7%, 31.7% and 51.2% at the 1st, 2nd and 3rd 
trimesters, respectively) and the overall prevalence of anemia was 15.8%. However, 
the proportions of these conditions increased with longer pregnancy duration. 
Medication for iron deficiency was prescribed to 57.3% of patients. 98.5% of anae-
mic women and respectively 97.8% and 73.6% of women at significant or moderate 
risk of iron deficiency were prescribed medications (most iron-based). Among 
women receiving treatment, 43.1% had clinical signs of anemia and 39.3% received 
systematic prevention iron . ConClusions: In French clinical practice, the iron 
deficiency isk and anemia prevalence during pregnancy align with medical 
expectations. These conditions are managed according to national/international 
recommendations.
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objeCtives: Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a rare, 
progressive, debilitating and life-threatening neurodegenerative disease. Although 
a rare disease, Portugal has one of the largest TTR-FAP foci in the world but recent 
Portuguese epidemiological data is lacking. The purpose of this study was to esti-
mate TTR-FAP prevalence in Portugal. Methods: TTR-FAP patient’s medicines utili-
zation is fully funded by National Health System in Portugal since 2001. Since March 
2013 Portuguese electronic prescription system became more generalized, allowing 
central monitoring and validation of medicines prescription and dispensing. TTR-
FAP anonymized patient’s data was requested to Administração Central do Sistema 
Saúde (ACSS). The most frequent municipality used for medicines dispensing by 
each patient was identified and used as a proxy for residence. Portuguese popula-
tion by municipality was obtained from Instituto Nacional Estatística. Prevalence 
was reported at country level and by municipality as number of cases per 100 000 
inhabitants. Results: Over the year 2014, two thousand and thirteen (2 013) TTR-
FAP anonymized patients were registered in ACSS database. A prevalence of 20 
per100 000 inhabitants was estimated for TTR-FAP in mainland Portugal. The dis-
ease is spread across 160 of the 278 Portuguese mainland Portuguese municipali-
ties. The municipalities with higher TTR-FAP prevalence are: Póvoa de Varzim (198), 
Pampilhosa da Serra (191), Seia (170), Esposende (138), Vila do Conde (136), Figueira 
da Foz (134), Boticas (111) and Barcelos (110). ConClusions: We can conclude 
that Portuguese ACSS electronic prescription database is useful, relevant and an 
accessible strategy to estimate the prevalence of some diseases in Portugal. We can 
estimate that TTR-FAP disease has a prevalence of 20 per 100 000 inhabitants and 
it is disseminated across the country being Póvoa de Varzim historically and still 
the most impacted municipality with 198 cases per 100 000 inhabitants, nearly ten 
times higher than country prevalence.
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objeCtives: Gene therapies for rare diseases have ignited industry-wide debates 
concerning patient access, pricing and efficacy. Urea cycle disorder (UCD), a genetic 
